Mediterranean Journal Of Pharmacy And Pharmaceutical Sciences

Thrombolytic therapy versus primary percutaneous coronary intervention: role of clinical pharmacist

• Authors Details :  
• Saadoun Omar El-mezughi,  
• Tarek Alzawawy,  
• Nawal Khalafalla

1.1K Views Research reports

Cardiovascular drugs constitute one of the largest and most widely used among other diseases and cardiovascular drug market has largely been exploded . Although these drugs have the potential to significantly improve the treatment of various cardiac diseases. They are potent agents with potential for serious adverse effects, toxicity and drug interactions. Newer agents are considerably costly than older drugs and, therefore, cost-effective strategies must be developed. Thrombolytics are pharmacological agents come from bacterial origin as streptokinase and staphylokinase or from human origin as urokinase or t-PA. Thrombolytics are used to restore blood flow to infracted artery quickly. Only streptokinase, alteplase, reteplase and tenecteplase are approved by US-FDA for treatment of ST-elevation myocardial infraction (ST-EMI) [3]. This reopens blood vessels after their occlusion and prevents tissue necrosis. Although, the safe and effective use of each of these drugs requires a thorough understanding of appropriate patient selection, drug timing, dosing regimens and monitoring parameters. The greatest benefit to risk ratio for specific drugs is seen in certain subsets of patients the complexities of cardiovascular drug therapy illustrate the need for an in depth current knowledge of clinical trial evidence.

Article DOI & Crossmark Data

DOI : https://doi.org/10.5281/zenodo.5805910

Article Subject Details

• Cardiovascular and pulmonary physiotherapy
• Clinical pharmacology
• Clinical pharmacy
• Pharmaceutical sciences
• Pharmacy

Article Keywords Details

• clinical pharmacist
• percutaneous coronary
• thrombolytic therapy
• Cardiovascular drugs

Article File

More Article by Mediterranean Journal of Pharmacy and Pharmaceutical Sciences